SCID-Xl is a catastrophic disease of childhood caused by mutations in the common gamma chain (YC) leading to defects in cytokine signaling that result in profound deficiencies in both cellular and humoral immunity. Patients that have a matched sibling donor for allogeneic transplant do very well with a greater than 90% long-term disease free survival. However, most patients do not have a matched sibling donor available and typically are treated using a haploidentical, parental transplant. These patients do significantly less well with a long term survival ranging between 60 and 75%. Furthermore, persistent immune defects are present in about 50 to 60 % of the survivors of haploidentical transplants. For these children who lack a matched sibling donor, gene therapy is being developed as an alternate primary therapy and as salvage for allogeneic transplant failures. Prior trials in France, the UK, and in the US have used retroviral vectors developed from the Moloney Leukemia Virus (MLV) in which the y{c} cDNA was driven from the strong viral enhancer/promoter present in the long terminal repeat (LTR). These trials have yielded clear proof of efficacy by showing that the majority of patients had significant immune reconstitution following the gene transfer procedure. However, 5 out of 23 patients have developed T cell leukemia due to transcriptional activation of cellular proto-oncogenes from the strong viral enhancer present in the MLV LTR. We now seek to avoid this complication by using a self-inactivating (SIN) lentiviral vector which contains an internal cellular promoter and chromatin insulator fragments flanking the transcriptional cassette. We have tested this CL20i4-EF1a-hy{c}-OPT vector in preclinical experiments that have confirmed the potential safety and efficacy of this configuration. We have also created a high titer, stable producer cell line for GMP production and have generated a Master Cell Bank in our GMP facility. We now propose two clinical protocols to study the use of this vector in either newly diagnosed patients less than one year old (LVXSCID-ND) or in older children that have failed previous treatment or who present later in life with milder symptoms (LVXSCID-OC). We hypothesize that this lentiviral vector-based approach will provide effective treatment and will be safer than the previous MLV-based vectors. These companion clinical trials should yield a great deal of information about gene therapy for SCID-X1 and more generally about the use of lentiviral vectors for stem cell-targeted, human gene therapy.

Public Health Relevance

This project will test a new method for treating patients with x-linked severe combined immunodeficiency based on using lentiviral vectors and may identify a new treatment option that could be used for the majority of these patients. It is also possible that this study could provide more general information about lentiviral vectors that will lead to new therapies for other types of blood and immune system disorders.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Program Projects (P01)
Project #
Application #
Study Section
Heart, Lung, and Blood Program Project Review Committee (HLBP)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
St. Jude Children's Research Hospital
United States
Zip Code
Zhao, Hui Fen; Abraham, Allistair; Kim, Yoon-Sang et al. (2017) Lentiviral Transfer of ?-Globin with Fusion Gene NUP98-HOXA10HD Expands Hematopoietic Stem Cells and Ameliorates Murine ?-Thalassemia. Mol Ther 25:593-605
De Ravin, Suk See; Wu, Xiaolin; Moir, Susan et al. (2016) Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med 8:335ra57
Abraham, Allistair; Kim, Yoon-Sang; Zhao, Huifen et al. (2016) Increased Engraftment of Human Short Term Repopulating Hematopoietic Cells in NOD/SCID/IL2r?null Mice by Lentiviral Expression of NUP98-HOXA10HD. PLoS One 11:e0147059
Wielgosz, Matthew M; Kim, Yoon-Sang; Carney, Gael G et al. (2015) Generation of a lentiviral vector producer cell clone for human Wiskott-Aldrich syndrome gene therapy. Mol Ther Methods Clin Dev 2:14063
Pestina, Tamara I; Hargrove, Phillip W; Zhao, Huifen et al. (2015) Amelioration of murine sickle cell disease by nonablative conditioning and ?-globin gene-corrected bone marrow cells. Mol Ther Methods Clin Dev 2:15045
Zhou, Sheng; Bonner, Melissa A; Wang, Yong-Dong et al. (2015) Quantitative shearing linear amplification polymerase chain reaction: an improved method for quantifying lentiviral vector insertion sites in transplanted hematopoietic cell systems. Hum Gene Ther Methods 26:4-12
Urbinati, Fabrizia; Hargrove, Phillip W; Geiger, Sabine et al. (2015) Potentially therapeutic levels of anti-sickling globin gene expression following lentivirus-mediated gene transfer in sickle cell disease bone marrow CD34+ cells. Exp Hematol 43:346-351
Treanor, Louise M; Zhou, Sheng; Janke, Laura et al. (2014) Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential. J Exp Med 211:701-13
Griffith, Linda M; Cowan, Morton J; Notarangelo, Luigi D et al. (2014) Primary Immune Deficiency Treatment Consortium (PIDTC) report. J Allergy Clin Immunol 133:335-47
De Ravin, Suk See; Gray, John T; Throm, Robert E et al. (2014) False-positive HIV PCR test following ex vivo lentiviral gene transfer treatment of X-linked severe combined immunodeficiency vector. Mol Ther 22:244-245

Showing the most recent 10 out of 152 publications